Shares of biotechnology outfit AbCellera Biologics (NASDAQ: ABCL) were up 17.2% as of mid-session Friday following encouraging commentary within its second-quarter report.
It certainly could have been worse.
For the three-month span ending in June, AbCellera Biologics turned $27.6 million worth of revenue into a loss of $0.01 per share. The bottom line compares unfavorably to the year-ago profit of $0.03 per share, although the top line was a marked improvement on the year-ago sales figure of $11.2 million.
For further details see:
Why AbCellera Biologics Stock Was Up More Than 17% on Friday